Hey,
After sending out the earlier email (below), I got nearly a number replies from readers who asked for the link to the RIKEN announcement about the iPSC study being resumed in humans.
It is a major announcement within the stem cell sector, so it makes sense that you'd want more information.
You can get details about the resumed iPSC study from this article on our site.
Or, here is a great overview by a Tokyo- based newspaper and the original article I read in the Japan Times. Enjoy!
Best,
Cade
On Wed, Jun 22, 2016 at 2:41 PM, Cade Hildreth wrote:
In major news, RIKEN announced that it is resuming its retinal induced pluripotent stem cell (iPSC) study in partnership with Kyoto University.
The first transplant of iPSC cells into humans occurred in 2014 when iPSC-derived retinal pigment epithelium cells were implanted into a patient with age-related macular degeneration in Kobe, Japan.
Unfortunately, the study was later suspended due to safety concerns. Now, nearly two years later, RIKEN has announced it will be resuming the world's first clinical study involving the use of iPSC-derived cells in humans.
To learn about this and other major iPSC market forces, claim the "Complete 2015-16 Induced Pluripotent Stem Cell Industry Report":
http://www.bioinformant.com/product/complete-2015-16-induced-pluripotent-stem-cell-ipsc-industry-report/
The market for iPSC-derived cells is growing. Are you informed about market opportunities and ready to act on them now?
Be Great,
Cade
President/CEO of BioInformant.com
"1st and Only Market Research Firm to Specialize in the Stem Cell Industry"
p.s. We are extremely proud of our client testimonials. You should also check out our "Greater than 100% Money Back Guarantee."
|
| |
